Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Male and/or female patients, ≥ 18 years of age with cold agglutinin disease as defined by:~  1. Chronic hemolysis per Investigator's judgement,~ 2. Polyspecific direct antiglobulin test (DAT) positive,~ 3. Monospecific DAT strongly positive for C3d,~ 4. Cold agglutinin (CAg) titer ≥ 64 at 4 C; and,~ 5. IgG DAT ≤1+.~* A hemoglobin level ≤11 mg/dL.~* A total bilirubin level above the normal reference range that is thought to be due to hemolysis.~* Documented vaccinations against encapsulated bacterial pathogens (Neisseria meningitidis, including serogroup B meningococcus and Streptococcus pneumoniae) within five years of screening or willing to complete protocol specified vaccinations.~* Having given written informed consent prior to undertaking any study-related procedure.~Exclusion criteria:~* Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high grade hematologic malignancy, or known solid organ tumor.~* Clinically relevant infection of any kind within one month preceding screening.~* Treatment with anti-CD20 monotherapy within three months or anti CD20 combination therapies within six months prior to screening.~* Concurrent treatment with systemic immunosuppressive agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening.~* Any specific complement system inhibitor within three months prior to screening.~* Concurrent treatment with systemic corticosteroids other than a stable daily dose equivalent to ≤10 mg/day prednisone within three months prior to screening.~* If female, pregnant or lactating.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIVV020 IV (Type: EXPERIMENTAL): Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).